Epigenetics· 2026Q1
A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples
- 2citations
- Q1SCImago
- 2026year
Short summary
A new Breast Tissue-specific Epigenetic Clock (BTEC) predicts chronological age in breast tissue with high accuracy (r=0.88, MAE=3.27 years), significantly outperforming pan-tissue models.
AI-generated from the title and abstract; the full text is not read.
Key points
- A novel Breast Tissue-specific Epigenetic Clock (BTEC) was developed and validated.
- BTEC achieved high accuracy in predicting chronological age in healthy breast tissue (r=0.88, MAE=3.27 years).
- BTEC outperformed pan-tissue epigenetic clocks in breast tissue prediction.
- Significant age de-correlation was observed in tumor-adjacent (-1.76 years) and tumor samples (-12.29 years), especially in HER2+ and TNBC subtypes.
- BTEC probes were linked to oncogenes and estrogen metabolism pathways.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly in predicting chronological age in breast tissue, underscoring the need for a tissue-specific approach. In this study, we introduce a Breast Tissue-specific Epigenetic Clock (BTEC), developed using DNA methylation data from 553 healthy breast tissue samples across seven different studies. BTEC significantly outperformed pan-tissue clocks, demonstrating superior correlation with chronological age (r=0.88) and lower prediction errors (MAE=3.27 years) without requiring for dataset-specific regressions adjustments. BTEC’s chronological age predictions for tumor-adjacent samples showed distortions, with an average deviation of -1.76 years, which was even more pronounced in tumor samples, where the average difference between predicted and chronological age was -12.29 years. When analyzed by molecular subtype, the distortion was greater in the more aggressive HER2+ and TNBC tumors compared to HR+ tumors. The probes used by BTEC were associated with known oncogenes, genes involved in estrogen metabolism, cadherin binding and fibroblast growth factor binding. Despite the general rejuvenation observed in tumor tissue compared to normal breast, the correlation between BTEC’s predictions and cancer-related survival indicated that TNBC tumors with increased epigenetic ages had significant lower survival.
The authors' abstract, as published at the source. Epigenetics, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Molecular Biology
Molecular BiologyBiochemistry, Genetics and Molecular Biology